Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia
Richter Syndrome

Interventions: Drug: Polatuzumab Vedotin
Drug: Rituximab
Drug: Etoposide
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Hydroxydaunomycin

First Posted Date: 2020-12-22

Last Posted Date: 2024-10-31

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 20

Registration Number: NCT04679012

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Mount Sinai- Icahn School of Medicine, New York, New York, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 1 locations

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Carboplatin
Drug: Tiragolumab Matching Placebo
Drug: Etoposide

First Posted Date: 2020-12-14

Last Posted Date: 2024-10-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 123

Registration Number: NCT04665856

Locations: 🇨🇳
Cancer Center of Guangzhou Medical University, Guangzhou, China
🇨🇳
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou City, China
🇨🇳
Zhongshan Hospital Fudan University, Shanghai, China

and more 13 locations

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma Unclassifiable
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Drug: Polatuzumab Vedotin
Biological: Rituximab

First Posted Date: 2020-12-14

Last Posted Date: 2024-08-26

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 41

Registration Number: NCT04665765

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

Phase 3

Recruiting

Conditions: Hodgkin Lymphoma, Adult

Interventions: Drug: Doxorubicin
Drug: Bleomycin
Drug: Vinblastine
Drug: Cyclophosphamide
Drug: Dacarbazine
Drug: Etoposide
Drug: Vincristine
Drug: Dexamethasone

First Posted Date: 2020-11-20

Last Posted Date: 2022-11-01

Lead Sponsor: State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia

Target Recruit Count: 300

Registration Number: NCT04638790

Locations: 🇮🇳
Tata Memorial Hospital, Mumbai, OPD-81 Main building, Dr. E Borges Road, Parel 400012, India
🇷🇺
The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow, Russian Federation

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

Phase 1

Completed

Conditions: Extensive Stage Lung Small Cell Carcinoma
Malignant Solid Neoplasm
Metastatic Malignant Neoplasm in the Brain

Interventions: Biological: Atezolizumab
Drug: Carboplatin
Drug: Entinostat
Drug: Etoposide

First Posted Date: 2020-11-17

Last Posted Date: 2023-10-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT04631029

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

and more 2 locations

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Small Cell Lung

Interventions: Drug: Atezolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
Radiation: Thoracic radiation therapy (TRT)

First Posted Date: 2020-11-09

Last Posted Date: 2024-07-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 56

Registration Number: NCT04622228

Locations: 🇨🇳
Cancer Hospital , Chinese Academy of Medical, Beijing City, China
🇨🇳
West China Hospital - Sichuan University, Chengdu City, China
🇨🇳
Second Affiliated Hospital of Third Military Medical University, Chongqing, China

and more 5 locations

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Phase 2

Terminated

Conditions: Brain Metastases
Small-cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Atezolizumab

First Posted Date: 2020-10-30

Last Posted Date: 2024-03-13

Lead Sponsor: Jeffrey Clarke

Target Recruit Count: 3

Registration Number: NCT04610684

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸
St. Vincent Anderson Regional Hospital, Anderson, Indiana, United States

and more 3 locations